GB202306126D0 - Treatment of rapamycin-sensitive conditions - Google Patents
Treatment of rapamycin-sensitive conditionsInfo
- Publication number
- GB202306126D0 GB202306126D0 GBGB2306126.0A GB202306126A GB202306126D0 GB 202306126 D0 GB202306126 D0 GB 202306126D0 GB 202306126 A GB202306126 A GB 202306126A GB 202306126 D0 GB202306126 D0 GB 202306126D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- rapamycin
- treatment
- sensitive conditions
- sensitive
- conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 229960002930 sirolimus Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2306126.0A GB202306126D0 (en) | 2023-04-26 | 2023-04-26 | Treatment of rapamycin-sensitive conditions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2306126.0A GB202306126D0 (en) | 2023-04-26 | 2023-04-26 | Treatment of rapamycin-sensitive conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202306126D0 true GB202306126D0 (en) | 2023-06-07 |
Family
ID=86605498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2306126.0A Pending GB202306126D0 (en) | 2023-04-26 | 2023-04-26 | Treatment of rapamycin-sensitive conditions |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB202306126D0 (en) |
-
2023
- 2023-04-26 GB GBGB2306126.0A patent/GB202306126D0/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202006665D0 (en) | Treatment of ischaemia | |
| GB202306126D0 (en) | Treatment of rapamycin-sensitive conditions | |
| IL291626A (en) | Treatment of celiac disease | |
| IL287250A (en) | Method of treatment | |
| GB201907305D0 (en) | Treatment of conditions | |
| GB201911056D0 (en) | Treatment of ADD/ADHD | |
| GB202307686D0 (en) | Treatment of conditions | |
| GB202101251D0 (en) | Treatment of conditions | |
| GB202315695D0 (en) | TReatment of cariomyopathy | |
| GB202212506D0 (en) | Treatment of covid-19 | |
| GB202201824D0 (en) | Methods of treatment | |
| GB202201825D0 (en) | Methods of treatment | |
| GB202201819D0 (en) | Methods of treatment | |
| LT4225291T (en) | Treatment of cholangiopathies with seladelpar | |
| GB202118011D0 (en) | Methods of treatment | |
| GB202118007D0 (en) | Methods of treatment | |
| GB202118006D0 (en) | Methods of treatment | |
| GB202108245D0 (en) | Methods of treatment | |
| GB202108242D0 (en) | Methods of treatment | |
| GB202005874D0 (en) | Methods of treatment | |
| GB201917253D0 (en) | Treatment of conditions | |
| IL313079A (en) | Methods of treatment using lou064 | |
| GB202103975D0 (en) | Treatment of HS | |
| GB202211632D0 (en) | Treatment of water | |
| GB202215264D0 (en) | Use of urolithins |